The allogeneic stem cell market stands at the forefront of regenerative medicine, offering remarkable promise for the treatment of various diseases. The allogeneic stem cell market is expected to grow at a CAGR of 6.5% during the forecast period of 2025 to 2033, driven by advancements in unmodified stem cell transplants, expanding applications in oncology, and emerging therapies for musculoskeletal diseases. Despite the restraint of graft-versus-host disease, the market demonstrates promise in addressing various medical conditions.
The lung cancer diagnostics market is pivotal in the early detection and management of lung cancer, a deadly disease with high mortality rates. The lung cancer diagnostics market is expected to grow at a CAGR of 7.5% during the forecast period of 2025 to 2033. The lung cancer diagnostics market plays a critical role in addressing the rising prevalence of lung cancer globally. Key drivers include the increasing burden of lung cancer, technological advancements, and the shift toward personalized medicine.
The small-volume parenteral (SVP) market is expected to grow at a CAGR of 7.8% during the forecast period of 2025 to 2033. The SVP market is poised for substantial growth, driven by factors such as the rising prevalence of chronic diseases, advancements in drug development, and demographic shifts. While regulatory challenges pose a restraint, the market is adapting to meet quality assurance requirements.
The liquid-handling technology market is expected to grow at a CAGR of 8.5% during the forecast period of 2025 to 2033, liquid-handling technology market plays a pivotal role in various scientific and medical domains by providing precise and automated solutions for the accurate handling of liquids. the Liquid Handling Technology market plays a vital role in advancing scientific research and pharmaceutical development. The drivers, including drug discovery, cancer genomics, and bioprocessing, continue to propel the market forward. However, the high initial costs and technical expertise required represent significant challenges.
The global chest drainage devices market is expected to grow at a CAGR of 5.5% during the forecast period of 2025 to 2033. The has witnessed steady growth over the years. The market's expansion is propelled by a trifecta of drivers: the relentless surge of medical technologies, the shifting tides of prevalent respiratory conditions, and the ever-growing need for adept post-operative care. These dynamic forces have propelled the market's growth, igniting innovation and raising patient care standards. However, the journey isn't without its challenges.
The cell and gene therapy manufacturing market is expected to grow at a CAGR of 17.3% during the forecast period of 2025 to 2033. The market has emerged as a groundbreaking sector within the biopharmaceutical industry, revolutionizing medical treatment through personalized therapies. The cell and gene therapy manufacturing market is driven by advancements in cellular engineering, rising disease prevalence, and a supportive regulatory environment. Complex manufacturing processes pose challenges that need to be addressed to ensure consistent product quality and reproducibility.
The ferrocene market is expected to grow at a CAGR of 6% during the forecast period of 2025 to 2033. Growing environmental consciousness and stringent environmental regulations are increasing the use of fuel additives and, consequently, ferrocene market demand. The pharmaceutical industry's demand for ferrocene has increased due to its anticancer, antibacterial, and antifungal properties. The global demand for ferrocene, particularly for anti-cancer drugs, is increasing due to the growing demand for cancer treatment.
The small molecule innovator contract development and manufacturing organization (CDMO) market is expected to experience a CAGR of 6.5% during the forecast period of 2025 to 2033, due to the increasing demand for outsourcing pharmaceutical development and manufacturing services. Small molecule drugs remain a dominant class of therapeutics, and innovative pharmaceutical companies are increasingly relying on CDMOs to accelerate drug development timelines, access specialized expertise, and optimize manufacturing processes.
The RNA therapy clinical trials market is expected to witness a CAGR of 4% during the forecast period of 2025 to 2033, driven by advancements in RNA-based therapeutic approaches and the potential for targeted and personalized treatments. RNA therapy involves the use of ribonucleic acid (RNA) molecules to target specific genes and modulate protein production, offering promising opportunities for treating various diseases, including cancer, genetic disorders, and infectious diseases.
The healthcare informatics market is expected to reach a CAGR of 13% during the forecast period of 2025 to 2033, driven by technological advancements, increasing demand for efficient healthcare systems, and a growing focus on digitization and data management in the healthcare industry. Healthcare informatics refers to the application of information technology and data science to enhance the efficiency, quality, and safety of healthcare delivery. The healthcare informatics landscape encompasses a wide array of products and services.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.